In late September, Aegros employees received a memo asking them to ensure their personal email addresses were up-to-date in the work system because they were about to lose access to their corporate accounts.
At most companies, this would come as a surprise. But Aegros, a blood plasma start-up hoping to rival ASX-listed giant CSL, had struggled to make payroll on time for much of the year. This was just another irritation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.